Clinical Trials Logo
  1. Home
  2. Epidermolysis Bullosa Simplex
  3. NCT00936533

Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita

Epidermolysis Bullosa Simplex Clinical Trial

Official title:
Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita - a Double-blind Placebo-controlled Phase II Proof of Concept Study

Clinical Trial Summary

This study evaluates the clinical effect of foot injection of the bacteria protein Botulinum toxin A on plantar pain in patients with EBS (epidermolysis bullosa simplex) or PC (pachyonychia congenita).

Clinical Trial Description

Epidermolysis bullosa simplex (EBS) is the most common subtype of epidermolysis bullosa and mutations in keratin genes (KRT 5/14) are responsible for this condition. Painful blisters and keratoderma of the feet are common and the blisters in EBS typically get worse in the summer due to sweating and increased environmental heat. Since 2010, also the related condition pachyonychia congenita (PC) is included in the study. The primary objective of the study is to evaluate the clinical effect of Botulinum toxin A (Dysport®), injected in the foot, on plantar pain in patients with EBS or PC. Quality of life, pain in feet, effect duration, plantar sweating and safety of the treatment will also be studied. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00936533
Study type Interventional
Source Uppsala University
Contact Carl Swartling
Phone +46 18 611 50 97
Status Recruiting
Phase Phase 2
Start date May 2009
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT02592954 - Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin Phase 1
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Completed NCT05062070 - Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex Phase 1
Recruiting NCT03016715 - Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Phase 2
Completed NCT02960997 - Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Phase 2
Completed NCT03472287 - To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) Phase 1
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Not yet recruiting NCT02470689 - Diacerin for the Treatment of Epidermolysis Bullosa Simplex Phase 2
Recruiting NCT03453632 - Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Phase 2/Phase 3
Terminated NCT03154333 - Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) Phase 2
Active, not recruiting NCT05033574 - The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Completed NCT04908215 - INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Phase 2
Completed NCT03389308 - Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex Phase 2